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Neste trabalho foi realizada a preparação de nanocápsulas de poli (DL-lactídeo-co-glicolídeo) 
(PLGA) como um sistema carreador para o anestésico local bupivacaína. A preparação foi 
caracterizada e sua estabilidade físico-química avaliada. Os resultados da caracterização mostram 
uma distribuição de tamanho com um índice de polidispersão de 0,12, um diâmetro médio de 
148 nm, um potencial zeta de –43,5 mV e uma eficiência de associação da BVC nas nanocápsulas 
de 75,8%. As propriedades físico-químicas das suspensões (diâmetro hidrodinâmico, índice de 
polidispersão, potencial zeta e eficiência de associação do fármaco) contendo nanocápsulas 
poliméricas foram avaliadas em função do tempo a fim de determinar sua estabilidade. Nenhuma 
grande alteração foi observada em função tempo para as suspensões de nanocápsulas avaliadas, 
sendo consideradas estáveis por um período de armazenagem de 120 dias a temperatura ambiente. 
Os resultados aqui apresentados, os quais se referem ao estudo desta nova formulação para 
anestésico local bupivacaína mostram-se promissores para futuros estudos in vivo.  
This paper describes the preparation of poly(DL-lactide-co-glicolide) (PLGA) nanocapsules 
as a drug carrier system for the local anesthetic bupivacaine. The system was characterized and its 
stability investigated. The results showed a size distribution with a polydispersity index of 0.12, 
an average diameter of 148 nm, a zeta potential of –43.5 mV and an entrapment efficiency of 
75.8%. The physicochemical properties of polymeric nanocapsule suspensions (average diameter, 
polydispersity, zeta potential and drug association efficiency) were evaluated as a function of time 
to determine the formulation stability. The formulation did not display major changes in these 
properties over the time, and it was considered stable up to 120 days of storage at room temperature. 
The results reported here which refer to the  initial characterization of these new formulations for 
the local anesthetic bupivacaine show a promising potential for future in vivo studies.
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Introduction
Numerous studies today are focusing on the development 
of new pharmaceutical formulations based on nanocarriers, 
which have demonstrated several advantages over 
conventional formulations, making this research line a 
promising and innovative area of the pharmaceutical sector.1,2
Polymer nanoparticles (PN) are carriers of drugs or other 
active molecules whose sizes range from 10 to 1000 nm. 
Nanospheres (NS) or nanocapsules (NC) can be obtained, 
depending on the method of preparation and the materials 
employed. NC consists of a polymer casing and a nucleus 
(usually oily). The drug inside the NC may be dissolved 
in the oily nucleus or adsorbed on the polymeric wall. NS, 
on the other hand, consists of a polymer matrix and their 
composition does not include oil. In this system, the drug 
may be adsorbed or dispersed in the polymeric matrix.2-6
Several polymers are used in the preparation of NS or 
NC; however, aliphatic polyesters are the most attractive for 
injectable systems due to their biodegradability, availability, 
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biocompatibility, absence of toxicity and because they 
are easy to incorporate into a wide range of drugs.7 The 
degradation of aliphatic polyesters may result from the 
enzymatic action and/or hydrolysis of the ester bond and 
may be affected by the properties of these polymers, such 
as their chemical composition, molar mass, solubility, 
hydrophobicity/hydrophilicity, transition temperature, 
structure (crystalline or amorphous), among other factors.8,9
The aliphatic polyesters most commonly used 
are poly(lactic acid) (PLA), poly(glycolic acid) 
(PGA),  poly(lact ic-co-glycolic acid)  (PLGA), 
poly(ε-caprolactone) (PCL), poly(hydroxyvalerate) (PHV) 
and poly(hydroxybutyrate) (PHB).4,10
Local anesthetics (LA) are molecules whose primary 
pharmacological activity involves reversible nerve 
conduction blockage.11,12 Although several physicochemical 
models have been proposed to explain how LA block 
nerve conduction, the principal mechanism involves its 
interaction at one or more specific sites in the sodium-
dependent channels of neural membranes.13-15
Bupivacaine (BVC) is a LA of the amino amide class, 
which, together with two other LA of this class, lidocaine 
and ropivacaine, are the drugs of choice in acute and chronic 
pain therapy. Bupivacaine is commercially available in 
formulations varying from 0.25 to 0.75% in mass of BVC.16,17
Because the desirable characteristics for a LA include 
long duration of action, selectivity for sensory rather than 
motor nerve block and reduction of systemic toxicity,17,18 an 
alternative that has proved able to promote these desirable 
effects is the modified release of these drugs through carrier 
systems. The purpose of release systems is to promote slow 
and continuous release, reducing the systemic toxicity of 
these locally active drugs.17-19 Drug release systems are, 
in fact, able to compartmentalize the active substance and 
drive it to specific active sites, as well as control the rate 
of release without altering the chemical structure of the 
transported molecule.20
The delivery of local anesthetics, which has been 
studied extensively by many research groups and also 
by our laboratory, can be achieved by the formation of 
inclusion complexes with cyclodextrins,20-30 encapsulation 
in liposomes,31-39 association to polymer microparticles40-43 
and association to polymeric nanostructured systems.44-48
The use of colloidal systems of polymeric nanoparticles 
is often limited due to problems of stability over long periods 
of time. A colloidal suspension does not normally show 
phase separation, since both sedimentation and aggregate 
formation are slow. However storage for many months can 
sometimes result in aggregation and consequently phase 
separation, which renders the use of such formulations non-
viable.4 Hence, the purpose of this work was to prepare, 
characterize and monitor the physicochemical stability of 
PLGA nanocapsules containing bupivacaine. This study is 
important for the characterization of a new pharmaceutical 
form for pain therapy.
Material and Methods 
The materials used were bupivacaine (free base, Cristália 
Ind. Farm. LTDA), poly(DL-lactide-co-glycolide, 50:50) 
(PLGA 50:50, MW 40,000-70,000 g mol-1) (Sigma  Aldrich 
Chem. Co.), sorbitan monostereate (Span60®) (Sigma 
Aldrich Chem. Co.), polysorbate 80 (Tween80®) (LabSynth, 
Brazil), caprylic/capric acid triglyceride (Miglyol 810®) 
(Hüls, Germany) and analytical grade acetone (LabSynth, 
Brazil). The solvents used for the chromatographic analyses 
were HPLC grade acetonitrile (JT Baker®) and Milli-Q water.
Preparation of the PLGA nanocapsules with bupivacaine 
 
The PLGA nanocapsules were prepared by the 
nanoprecipitation method,49 which involved mixing an 
organic phase in an aqueous phase. The organic phase 
consisted of PLA polymer (100 mg), acetone (30 mL), 
bupivacaine (25 mg), sorbitan monostereate (40 mg) and 
caprylic/capric acid triglyceride (200 mg). The aqueous 
phase was composed of polysorbate 80 (60 mg) and 
deionized water (30 mL). After the dissolution of the 
components of both phases, the organic phase was gradually 
added to the aqueous phase using a small funnel. The 
resulting suspension was kept under agitation for 10 min, 
after which it was concentrated under low pressure to a 
volume of 10 mL, using a rotary evaporator, in order to 
obtain a suspension of bupivacaine with a concentration of 
2.5 mg mL-1. A control formulation without bupivacaine was 
also prepared, following the methodology described above.
Size and polydispersity measurements
The dynamic light scattering technique was used to 
determine the mean particle size (hydrodynamic diameter) 
and polydispersity. These analyses were performed by 
diluting (1:1000, v/v) the nanocapsule suspensions (with 
and without BVC) and using a ZetaPlus® particle analyzer 
with 90º fixed angle detector, at a temperature of 25 ºC. 
The size distribution and polydispersity were measured 
and were expressed as the mean of five determinations.
Zeta potential measurements
The value of the zeta potential, expressed in mV, 
was determined using a ZetaPlusâ potential analyzer. 
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The analyses were carried out by diluting (1:1000, v/v) 
the nanocapsule suspensions (with and without BVC) in 
Milli-Q water, and the results were expressed as means of 
eight determinations.
Efficiency of bupivacaine association in PLGA nanocapsules
The percentage of BVC associated to the nanocapsules 
was determined by the ultrafiltration/centrifugation 
method. The nanocapsule samples containing bupivacaine 
were centrifuged in ultrafiltration filters composed 
of regenerated cellulose with 30 kDa molecular size-
exclusion pores (Microcon -Millipore®), and the 
filtrate was quantified by high performance liquid 
chromatography (HPLC). The concentration of BVC was 
determined using an analytical curve (concentration range: 
1-200 mg mL-1, peak area = 3.30×105[bupivacaine] + 
4.7×105, r = 0.9998, n = 6). The specificity was tested 
in the presence of the colloidal suspension components, 
and it was demonstrated that these factors did not alter 
bupivacaine quantification.
The BVC association rate was determined from the 
difference between the drug concentration measured in the 
filtrate and its total concentration (100%) in the nanocapsule 
suspension.
The chromatographic conditions employed in 
the quantification were: mobile phase composed of 
acetonitrile/phosphate buffer (pH 7.4, 5 mmol mL–1, 
i.e., 3 mmol L–1 Na2HPO4 and 2 mmol L–1 NaH2PO4, 
85:15, v/v), 2.3 mL min–1 flow rate, and a Phenomenex 
Gemini chromatographic column (C18 reversed phase, 
5 μ, 110 Å, 150 × 4.60 mm). The BVC was detected 
at a wavelength of 220 nm, using an ultraviolet (UV) 
detector. The injection volume was 20 μL and all the 
injected samples were previously filtered through a 
0.22 μmol L-1 polyethersulfone membrane (Millipore®). 
The total BVC (100%) in the PLGA nanocapsule 
suspension was determined by diluting the suspension in 
acetonitrile. Acetonitrile is able to dissolve the polymer, 
thus completely releasing the BVC which, in turn, was 
quantified based on the analytical curve validated by 
Resolution RE No. 899/2003 of ANVISA, Brazil’s 
National Health Surveillance Agency.
Colloidal stability measurements 
The stability of the PLGA NC suspensions containing 
BVC was evaluated upon determinations of size, 
polydispersity, zeta potential and association rate as a 
function of time (zero, 15, 60 and 120 days), with the 
suspensions stored in amber glass flasks at room temperature. 
Results and Discussion
Measurements of the size (hydrodynamic diameter), 
polydispersity and zeta potential of particles are parameters 
that indicate the stability of nanocapsules in suspension. 
Table 1 lists the measured values of these parameters for the 
PLGA NC suspensions with BVC, as well as the association 
rate of this drug in the nanocapsules.
The results presented in Table 1 indicate that the 
PLGA NC suspensions with BVC presented a size 
(hydrodynamic diameter) and polydispersity compatible 
with colloidal suspensions.50 The zeta potential values 
of these formulations indicate good stability in solution, 
because they were lower than –30 mV and aggregation of 
particles in suspension was therefore avoided.4,5,52 
The BVC association rate in the PLGA nanocapsules 
was 75.8%, which is a very high value when compared 
to other studies reported in the literature for local 
anesthetics.44-48
The stabilities of the NC polymer suspensions containing 
BVC were evaluated based on the physicochemical 
properties of size, polydispersity, zeta potential and 
association efficiency as a function of time (initial, 15, 60 
and 120 days), with all the samples stored in amber glass 
flasks at room temperature. 
The graph in Figure 1(a) shows the particle size 
distribution by intensities obtained with the DTS nano 
software from light-scattering measurements of the PLGA 
NC containing BVC.
The results depicted in Figure 1(a) indicate that the 
size distribution in the formulation remained constant and 
unimodal for a period of 120 days, confirming the good 
conditions for preparation of the NC suspensions. Figure 1(b) 
also demonstrates that the particle size in the PLGA NC 
containing BVC was initially 147 nm, and underwent a slight 
increase up to 60 days, after which the particle size was found 
to decrease. Similar results for polymer nanoparticle sizes 
have been reported in the literature.50,51,53
Another parameter investigated was polydispersity, 
an index that can be indicative of stability, since it 
Table 1. Values of the mean diameter (hydrodynamic diameter, nm), 
polydispersity, zeta potential (mV) and association rate of the PLGA NC 
suspensions with BVC
Parameter PGLA-NC: BVC
Mean diameter (nm) 148
Polydispersity 0.12
Association rate (%) 75.8
Zeta potential (mV) -43.5
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represents the particle size distribution range. High 
polydispersity indices indicate size heterogeneity of 
particles in suspension, while variations in polydispersity 
values as a function of time indicate the formation of 
populations of particles with sizes that did not exist 
initially, possibly resulting from particle aggregation 
or breakdown/degradation. Polydispersity indices lower 
than 0.2 are ideal, because they indicate that the particle 
size distribution falls within a narrow range of sizes. 
Figure 2 shows the values of polydispersity as a function 
of time for the PLGA NC containing BVC.
The polydispersity of the NC suspension with BVC 
did not present statistically significant differences in 
polydispersity index as a function of time. All the results 
indicated good polydispersity indices, since they were all 
below 0.2. 
The zeta potential, which reflects the load on the particle 
surface, was another parameter evaluated here. In the 
absence of steric mechanisms, the stability of nanoparticles 
is determined by the balance of repulsion and attraction 
forces that the particles present. Thus, high repulsion 
forces tend to prevent aggregation. Nanoparticles with a 
zeta potential of approximately (±) 30 are more stable in 
suspension.4,5 Figure 3 shows the zeta potential graph of 
the particles as a function of time.
The PLGA NC suspension containing BVC showed 
an initial zeta potential of –43.5 mV, which changed 
progressively, reaching –30.2 mV in 120 days (Figure 3), 
thus indicating the formulation’s good stability. This 
observed change in the zeta potential could be due to a 
series of factors, especially changes in the interactions 
between pharmaceutical/polymer/surfactant at the surface 
of the polymeric nanocapsules. Previous published works 
have shown that surfactants54 and pharmaceuticals55 can 
modify zeta potential values in colloidal systems. However, 
more work is needed to better understand these changes.
The drug association rates in the nanoparticles were also 
evaluated as a function of time, as illustrated in Figure 4. 
The PLGA NC suspension with BVC showed a constant 
decline in the drug association rate up to 60 days, after 
which the rate gradually stabilizes by day 120 (Figure 4). 
The association rate varied from an initial 75.8% to 66.1% 
by day 120. According to Müller and co-workers,51 such 
a decline in drug association efficiency in NC may be due 
Figure 2. Polydispersity of particles as a function of time (0, 15, 60 
and 120 days) for PLGA NC suspensions with BVC. The dotted line 
indicates the maximum value of the polydispersity index for the particle 
size distribution range (0.2).
Figure 3. Zeta potential of particles as a function of time (0, 15, 60 and 
120 days) for PLGA NC suspensions with BVC.
Figure 1. a) Particle size distribution (nm) by intensity (%) of the PLGA 
formulation with BVC at 1, 15 and 120 days; b) Particle size (nm) as 
a function of time (0, 15, 60 and 120 days) for PLGA NC suspensions 
with BVC.
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to precipitation of nanocrystals of the drug during the 
formation of NC stabilized by surfactant agents. It was 
reported that these nanocrystals present the same size 
distribution as the NC, and therefore do not pass through 
the membrane used in the ultrafiltration/centrifugation 
procedure. Over time, these nanocrystals aggregate and 
precipitate, reducing the drug association rate in the NC. 
Guterres et al.50 demonstrated that nanocapsules of 
PLA/triglycerides containing dichlofenac showed the 
formation of nanocrystals that were initially stabilized by 
surfactants, and over the time formed agglomerates, with 
consequent precipitation.
Another factor that could explain the reduced association 
rate of the BVC molecule with time, in the PLGA NC, could 
be its release from the NC. However, the release profile 
was not investigated in the present study, because it was 
not possible to achieve dilution sink conditions due to the 
quantity of BVC present in the formulation.
Conclusions
This work provided several important pieces of 
information about the development of formulations 
containing PLGA NC with BVC, based on the method 
of interfacial deposition of preformed polymers. 
The NC polymer suspensions containing this local 
anesthetic presented good physicochemical stability as 
a function of time, in terms of size, polydispersity and 
zeta potential, since these parameters hardly altered 
with time. Concerning the association rate, a reduction 
of the amount of BVC in the PLGA NC was observed, 
probably due to formation of nanocrystals of the 
pharmaceutical. We therefore suggest that the system 
of BVC associated with PLGA nanocapsules could be 
a useful new formulation, since BVC is a long-lasting 
local anesthetic.
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